OMALIZUMAB

omalizumab 75 mg/0.5 mL injection, 0.5 mL syringe

OMALIZUMAB (10967F)

omalizumab 75 mg/0.5 mL injection, 0.5 mL syringe
10967F
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Uncontrolled severe allergic asthma
Treatment phase: Initial treatment - Initial 1 (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS-subsidised biological medicine therapy)

Restriction

Indication: Uncontrolled severe allergic asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 6 DPMQ: $104.54 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Omlyclo
Xolair